Patents Assigned to Merck
  • Inertion funnel
    Patent number: 10213784
    Abstract: An inertion funnel includes a hollow ring with an attachment point on an outside edge and a plurality of output apertures on the inside edge allows for an even flow of gas around the circumference of the ring and through the output apertures into a filter funnel below. The attachment point allows the attachment of a hose or other fitting through which gas flows into the hollow ring, which rests above and around the opening of the filter funnel. On the inside of the ring, an angled downward opening allows gas to flow out of the ring and into the filter funnel. Uniformly distributed around the opening are vanes that direct the flow of gas from the ring into the filter funnel below.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew Franklin Hagan, Mark Dennis Weisel
  • Btk inhibitors
    Patent number: 10214546
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • Thermally conductive, plate-shaped pigment coated with aluminium oxide
    Patent number: 10214673
    Abstract: The present invention relates to thermally conductive pigments which consist of a substrate and a coating applied thereto comprising aluminum oxide and/or aluminum oxide hydrate, to a process for the preparation of these pigments, and to the use thereof.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 26, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Reinhold Rueger, Matthias Kuntz
  • Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
    Patent number: 10213429
    Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joie Garfunkle, Olga Ornoski, Dann L. Parker, Jr., Subharekha Raghavan, Libo Xu, Zhiqiang Yang
  • Hydroxmethyl piperidine orexin receptor antagonists
    Patent number: 10214535
    Abstract: The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Factor XIA inhibitors
    Patent number: 10214512
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
  • MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20190058133
    Abstract: The present invention relates to compounds comprising a heterocyclic group substituted with a fluoranthene group and a particular aromatic or heteroaromatic group. The compounds are suitable for use in electronic devices, in particular organic electroluminescent devices, comprising these compounds. In some embodiments, the compounds are used as matrix materials for phosphorescent or fluorescent emitters as well as a hole-blocking or an electron-transport layer.
    Type: Application
    Filed: October 6, 2016
    Publication date: February 21, 2019
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain PARHAM, Tobias GROSSMANN, Jonas Valentin KROEBER
  • SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES
    Publication number: 20190055546
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: October 3, 2018
    Publication date: February 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS
    Publication number: 20190055216
    Abstract: The present invention relates to processes for the preparation of N-protected 4-((2S,5R)-5-((benzyloxy)amino)piperidine-2-carboxamido)piperidine-1-carboxylates. Such compounds have application in the preparation of beta-lactamase inhibitors such as 7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and esters, in particular, the beta lactamase inhibitor, (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also encompasses intermediates useful in the disclosed processes and methods for their preparation.
    Type: Application
    Filed: January 30, 2017
    Publication date: February 21, 2019
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME LIMITED
    Inventors: Aaron M. Dumas, Jeremy P. Scott, Michael Shevlin, Zhijian Liu, John Y. L. Chung, Feng Yu, Dongfang Meng
  • Sustained release formulation and tablets prepared therefrom
    Patent number: 10207002
    Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pranav Gupta, David Monteith
  • Liquid-crystalline medium
    Patent number: 10208251
    Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, Z1, Z2 and L1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 19, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Harald Hirschmann, Monika Bauer, Martina Windhorst, Marcus Reuter, Constanze Brocke, Rocco Fortte, Matthias Bremer, Sabine Schoen
  • Sample preparation container
    Patent number: 10207016
    Abstract: A sample preparation container, preferably for use in sterility testing, comprising a housing (1) having a housing wall (2) defining an inside space (3), a support on which a membrane filter is placed or is to be placed so as to get in contact with a sampling fluid to be introduced into the inside space (3), and at least one inlet opening (4) to the inside space (3) and at least one outlet opening from the inside space (3). A sampling port (5) is provided for allowing access from the outside to the inside space (3), wherein said sampling port (5) is closed by a septum (6) and the septum (6) is separated from the inside space (3) by a barrier wall (7) which is preferably piercable or breakable on application of an external force, preferably applied through a sampling instrument like a needle (8).
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Gerard Muller, Mathieu Arrault
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10208060
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, John Debenham, Xiaoxing Du, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Weiguo Quan, Christopher Sinz, Liping Wang
  • Tertiary alcohol imidazopyrazine BTK inhibitors
    Patent number: 10208047
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Brian M. Andresen, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • GLYCINE PARTICLES
    Publication number: 20190047942
    Abstract: The present invention relates to compacted glycine granules, where at least 75% of the granules have a particle size of above 0.7 mm, and to a process for the preparation and use of granules of this type.
    Type: Application
    Filed: January 24, 2017
    Publication date: February 14, 2019
    Applicant: Merck Patent GmbH
    Inventors: Harald BENK, Gudrun BIRK, Melina DECKER, Dieter LUBDA, Guenter MODDELMOG, Harald MUESSIG, Tanino SCARAMUZZA, Michael SCHLEEHAHN
  • RECOMBINANT EXPRESSION OF CHLAMYDIA MOMP ANTIGEN
    Publication number: 20190046626
    Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.
    Type: Application
    Filed: November 16, 2015
    Publication date: February 14, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Puneet Khandelwal, Ping Qiu
  • COMPOUNDS FOR THE TREATMENT OF MALARIA
    Publication number: 20190046507
    Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: February 13, 2017
    Publication date: February 14, 2019
    Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
  • Hydroxy-ethylene derivatives for the treatment of arthrosis
    Patent number: 10202418
    Abstract: The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: February 12, 2019
    Assignee: MERCK PATENT GMBH
    Inventor: Markus Klein
  • Substituted quinolizine derivatives useful as HIV integrase inhibitors
    Patent number: 10201533
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, Yonglian Zhang, Sherman Tim Waddell, John M. Sanders, Thomas H. Graham, Hong Li
  • Polycyclic compounds
    Patent number: 10205106
    Abstract: The present invention relates to compounds having polycyclic structural units and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: February 12, 2019
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Dominik Joosten, Nils Koenen